Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia

Imatinib, a BCR-Abl inhibitor, is a successful front-line treatment for chronic myelogenous leukemia (CML). Despite the success of imatinib, multiple mechanisms of resistance remain a problem, including overexpression of Lyn kinase (Lyn) and Bcl-2 family antiapoptotic proteins. Profiling micro-RNA (...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Zimmerman, Eric I., Dollins, Claudia M., Crawford, Melissa, Grant, Steven, Nana-Sinkam, Serge P., Richards, Kristy L., Hammond, Scott M., Graves, Lee M.
Format: Artigo
Idioma:Inglês
Publicat: The American Society for Pharmacology and Experimental Therapeutics 2010
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2981365/
https://ncbi.nlm.nih.gov/pubmed/20693279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/mol.110.066258
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars